Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. PW Medtech Group's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was €17.17 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was €32.54 Mil.
PW Medtech Group (FRA:PWE) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
PW Medtech Group Selling, General, & Admin. Expense Related Terms
PW Medtech Group Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PW Medtech Group Selling, General, & Admin. Expense Chart
FRA:PWE vs ISRG, BDX, MDLN: Selling, General, & Admin. Expense Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's Selling, General, & Admin. Expense falls into.
PW Medtech Group Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €32.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of €32.54 Mil mean?
PW Medtech Group (FRA:PWE) has a Selling, General, & Admin. Expense of €32.54 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on PW Medtech Group and its competitors.
Is PW Medtech Group's Selling, General, & Admin. Expense too high?
PW Medtech Group's current Selling, General, & Admin. Expense is €32.54 Mil. Overall, PW Medtech Group has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Selling, General, & Admin. Expense compare to ISRG and BDX?
PW Medtech Group's Selling, General, & Admin. Expense of €32.54 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on PW Medtech Group and its competitors. PW Medtech Group's current Selling, General, & Admin. Expense is €32.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
Based on GuruFocus' analysis, PW Medtech Group (FRA:PWE) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.13, compared to a current price of €0.10 — trading 25% below its estimated fair value. The current Selling, General, & Admin. Expense is €32.54 Mil. PW Medtech Group's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Selling, General, & Admin. Expense is €32.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.10 is trading 25% below its estimated GF Value™ of €0.13.
GuruFocus considers PW Medtech Group to be Significantly Undervalued.
Key valuation signals for FRA:PWE:
Selling, General, & Admin. Expense: €32.54 Mil
GF Value™: €0.13 vs. price of €0.10 (25% below fair value)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
82GF Score
Get the complete analysis for FRA:PWE
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
